Skip to main content

Table 3 Multigene predictors of response to endocrine treatment

From: Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction

Authors Signature Number of casesa Treatment Context Method Platform
Jansen et al. [110] 44 genes 48 training set, 66 validation set TAM Recurrent breast cancer Top-down (response vs. progression) Microarray (local)
Loi et al. [112] Tamoxifen predictor (181 genes) 99 training set, 69 validation set
87 validation set
TAM Adjuvant treatment Top-down (relapse vs. no relapse) Microarray (Affymetrix, Santa Clara, CA, USA)
Oh et al. [111] Estrogen-regulated genes (822 genes) Cell lines + 65 discovery set, 60 validation set (1) Heterogeneous TAM (1) Adjuvant treatment Bottom-up (estrogen induced gene expression changes in MCF-7 cell lines) Microarray (Agilent Technologies, Inc., Santa Clara, CA, USA)
   90 validation set (2) TAM +/- NAC (2)    
   250 validation set (3) Heterogeneous (3)    
Symmans et al. [113] SET index (165 genes) 437 training set, 225 + 298 validation set (1) Heterogeneous TAM (1) Adjuvant treatment Bottom-up (genes coexpressed with estrogen receptor) Microarray (Affymetrix)
   122 validation set (2) NAC + TAM or Al (2)    
   208 + 133 validation set (3) Non-treated (3)    
  1. aNumber of cases in training and validation sets. AI, aromatase inhibitor; NAC, neoadjuvant chemotherapy; SET, sensitivity to endocrine therapy; TAM, tamoxifen.